Crinetics Pharmaceuticals, Inc.
CRNX
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as weā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$40.00
Price-8.03%
-$3.49
1Y
Price
Market Cap
$3.767b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-12523.0%
EBITDA Margin-11216.0%
Net Profit Margin-8637.5%
Free Cash Flow MarginRevenue
$1.392m
+34.0%
1y CAGR-18.5%
3y CAGR+71.0%
5y CAGREarnings
-$369.834m
-23.9%
1y CAGR-31.3%
3y CAGR-36.5%
5y CAGREPS
-$4.11
-11.4%
1y CAGR-9.5%
3y CAGR-10.3%
5y CAGRBook Value
$1.172b
$1.290b
Assets$118.048m
Liabilities$49.936m
DebtDebt to Assets
3.9%
-0.1x
Debt to EBITDAFree Cash Flow
-$307.798m
-33.9%
1y CAGR-38.2%
3y CAGR-36.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company